In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control
- PMID: 38560905
- DOI: 10.7326/J24-0014
In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control
Abstract
Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986.
Conflict of interest statement
Comment on
-
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. Lancet. 2024. PMID: 38071986 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical